Sign Up
OverviewAPI
Acelyrin, Inc. appoints Ken Lock as Chief Commercial Officer, bringing 20 years of immunology sales and marketing expertise to the late-stage clinical biopharma company. Acelyrin currently has a robust portfolio with late-stage clinical trials supporting potential commercial launches in the coming years. Lock's experience includes serving as Chief Commercial Officer at Arcutis Biotherapeutics and holding sales and marketing roles at Gilead Sciences, Amgen, and Wyeth (now Pfizer). Acelyrin is focused on developing transformative medicines in immunology and aims to address unmet needs in autoimmune and inflammatory diseases.

Ask a question